Loading asset research
Enveric Biosciences Inc. Common Stock
ENVBNasdaq · USD · StocksQuote as of · Exchange session not verified$1.44
-1.37%
Today
ENVB
Loading 1D prices…
Market cap
$6.4M
Volume
38.7K
52w high
$13.2552w low
$1.17Company profile
Enveric Biosciences Inc. Common Stock
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Cambridge, MA, United States
Employees
5
Fiscal year end
1231
CIK
890821
Session & valuation
Open$1.45
Previous close$1.46
Day high$1.48
Day low$1.42
30-day avg. volume109.4K
Outstanding shares4.5M
Diluted EPS-$36.24
Latest annual period
P/E (trailing)-0.04
P/E (forward)-1.01
Price / book0.69
Beta1.11
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| XTLBXTL Biopharmaceuticals Ltd. American Depositary Shares | $6.3M | $0.00 | — | -$0.80 | +1.59% | Unrated |
| ACXPAcurx Pharmaceuticals Inc. Common Stock | $6M | $0.00 | — | -$5.32 | 0.00% | Buy |
| KAPAKairos Pharma Ltd. Common Stock | $6M | $0.00 | — | -$0.30 | +4.64% | Buy |
| DRMADermata Therapeutics Inc. Common Stock | $5.9M | $0.00 | — | -$8.16 | -0.83% | Buy |
| PCSAProcessa Pharmaceuticals Inc. Common Stock | $5.8M | $0.00 | — | -$10.36 | +12.43% | Buy |